OTCPK:BMXM.F

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

bioMérieux S.A. provides vitro diagnostic solutions systems for private and hospital laboratories, primarily for the diagnosis of infectious diseases. More Details

Rewards

Earnings are forecast to grow 10.01% per year

Earnings grew by 16% over the past year

Risk Analysis

No risks detected for BMXM.F from our risk checks.


Snowflake Analysis

Excellent balance sheet with proven track record.


Similar Companies

Share Price & News

How has bioMérieux's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: BMXM.F has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

4.4%

BMXM.F

1.6%

US Medical Equipment

2.3%

US Market


1 Year Return

89.5%

BMXM.F

19.1%

US Medical Equipment

17.2%

US Market

Return vs Industry: BMXM.F exceeded the US Medical Equipment industry which returned 17.1% over the past year.

Return vs Market: BMXM.F exceeded the US Market which returned 15.8% over the past year.


Shareholder returns

BMXM.FIndustryMarket
7 Day4.4%1.6%2.3%
30 Day3.3%-2.3%-4.6%
90 Day8.5%9.7%7.4%
1 Year89.5%89.5%20.1%19.1%19.8%17.2%
3 Year87.2%87.2%70.5%66.0%37.4%28.3%
5 Year45.3%45.3%145.9%127.1%83.8%63.0%

Price Volatility Vs. Market

How volatile is bioMérieux's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is bioMérieux undervalued compared to its fair value and its price relative to the market?

51.94x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: BMXM.F ($155) is trading above our estimate of fair value ($79.03)

Significantly Below Fair Value: BMXM.F is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: BMXM.F is poor value based on its PE Ratio (51.4x) compared to the US Medical Equipment industry average (49.6x).

PE vs Market: BMXM.F is poor value based on its PE Ratio (51.4x) compared to the US market (18x).


Price to Earnings Growth Ratio

PEG Ratio: BMXM.F is poor value based on its PEG Ratio (5.1x)


Price to Book Ratio

PB vs Industry: BMXM.F is overvalued based on its PB Ratio (6.6x) compared to the US Medical Equipment industry average (4x).


Next Steps

Future Growth

How is bioMérieux forecast to perform in the next 1 to 3 years based on estimates from 11 analysts?

10.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: BMXM.F's forecast earnings growth (10% per year) is above the savings rate (2.2%).

Earnings vs Market: BMXM.F's earnings (10% per year) are forecast to grow slower than the US market (22.8% per year).

High Growth Earnings: BMXM.F's earnings are forecast to grow, but not significantly.

Revenue vs Market: BMXM.F's revenue (5.9% per year) is forecast to grow slower than the US market (9.9% per year).

High Growth Revenue: BMXM.F's revenue (5.9% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: BMXM.F's Return on Equity is forecast to be low in 3 years time (14.1%).


Next Steps

Past Performance

How has bioMérieux performed over the past 5 years?

17.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: BMXM.F has high quality earnings.

Growing Profit Margin: BMXM.F's current net profit margins (10.6%) are higher than last year (10.4%).


Past Earnings Growth Analysis

Earnings Trend: BMXM.F's earnings have grown by 17.8% per year over the past 5 years.

Accelerating Growth: BMXM.F's earnings growth over the past year (16%) is below its 5-year average (17.8% per year).

Earnings vs Industry: BMXM.F earnings growth over the past year (16%) exceeded the Medical Equipment industry 1.8%.


Return on Equity

High ROE: BMXM.F's Return on Equity (12.6%) is considered low.


Next Steps

Financial Health

How is bioMérieux's financial position?


Financial Position Analysis

Short Term Liabilities: BMXM.F's short term assets (€1.8B) exceed its short term liabilities (€1.2B).

Long Term Liabilities: BMXM.F's short term assets (€1.8B) exceed its long term liabilities (€524.7M).


Debt to Equity History and Analysis

Debt Level: BMXM.F's debt to equity ratio (27.4%) is considered satisfactory.

Reducing Debt: BMXM.F's debt to equity ratio has increased from 26.5% to 27.4% over the past 5 years.

Debt Coverage: BMXM.F's debt is well covered by operating cash flow (74.9%).

Interest Coverage: BMXM.F's interest payments on its debt are well covered by EBIT (23.8x coverage).


Balance Sheet


Next Steps

Dividend

What is bioMérieux current dividend yield, its reliability and sustainability?

0.14%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: BMXM.F's dividend (0.14%) isn’t notable compared to the bottom 25% of dividend payers in the US market (1.71%).

High Dividend: BMXM.F's dividend (0.14%) is low compared to the top 25% of dividend payers in the US market (4.83%).


Stability and Growth of Payments

Stable Dividend: BMXM.F is not paying a notable dividend for the US market, therefore no need to check if payments are stable.

Growing Dividend: BMXM.F is not paying a notable dividend for the US market, therefore no need to check if payments are increasing.


Current Payout to Shareholders

Dividend Coverage: BMXM.F is not paying a notable dividend for the US market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of BMXM.F's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.5yrs

Average management tenure


CEO

Alexandre Mérieux (46 yo)

2.75yrs

Tenure

€1,065,712

Compensation

Mr. Alexandre Mérieux serves as the Chairman and Chief Executive Officer of bioMérieux, Inc. Mr. Mérieux serves as the President and Chairman of the Management Board of Merieux Développement SAS. He joined ...


CEO Compensation Analysis

Compensation vs Market: Alexandre's total compensation ($USD1.25M) is below average for companies of similar size in the US market ($USD11.35M).

Compensation vs Earnings: Alexandre's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Alexandre Mérieux
Chairman & CEO2.75yrs€1.07m0.000050%
€ 9.3k
Frédéric Besème
Employee Director & Head of CSR2.33yrs€25.00k0.0025%
€ 461.1k
Guillaume Bouhours
Executive VP of Purchasing and Information Systems & CFO2.5yrsno datano data
Pierre Boulud
Executive VP of Clinical Operations & COOno datano datano data
Sylvain Morgeau
Investor Relationsno datano datano data
Esther Wick
Executive Vice President of Legalno datano datano data
Valérie Leyldé
Executive VP of Human Resources & Communications1.67yrsno datano data
François Lacoste
Executive Vice President of R&D2.5yrsno datano data
Mark Miller
Executive VP & Chief Medical Officer7.92yrsno datano data
Pierre Charbonnier
Executive Vice President of Global Quality2.5yrsno datano data
Yasha Mitrotti
Executive Vice President of Industrial Microbiology2.5yrsno datano data

2.5yrs

Average Tenure

47.5yo

Average Age

Experienced Management: BMXM.F's management team is considered experienced (2.5 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Alexandre Mérieux
Chairman & CEO2.75yrs€1.07m0.000050%
€ 9.3k
Frédéric Besème
Employee Director & Head of CSR2.33yrs€25.00k0.0025%
€ 461.1k
Alain Merieux
Founding Chairman3.08yrsno datano data
Jean-Luc Belingard
Non-Independent Director14yrs€44.00k0.00013%
€ 24.2k
Philippe Archinard
Non-Independent Director10.25yrs€51.00k0.000030%
€ 5.6k
Harold Y. Boël
Independent Director8.33yrs€51.00k0.00013%
€ 24.2k
Agnès Lemarchand
Independent Director6.33yrs€42.00k0.00013%
€ 24.2k
Marie-Helene Habert-Dassault
Independent Director8.33yrs€36.00k0.000050%
€ 9.3k
Fanny Letier
Independent Director3.33yrs€36.00k0.000030%
€ 5.6k
Marie-Paule Kieny
Independent Director3.08yrs€33.00k0.00015%
€ 27.9k

4.8yrs

Average Tenure

62.5yo

Average Age

Experienced Board: BMXM.F's board of directors are considered experienced (4.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

bioMérieux S.A.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: bioMérieux S.A.
  • Ticker: BMXM.F
  • Exchange: OTCPK
  • Founded: 1963
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: €15.835b
  • Listing Market Cap: €18.594b
  • Shares outstanding: 118.35m
  • Website: https://www.biomerieux.com

Number of Employees


Location

  • bioMérieux S.A.
  • 376 Chemin De l’Orme
  • Marcy l'Etoile
  • Rhône-Alpes
  • 69280
  • France

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BMXM.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDJul 2004
BIMENXTPA (Euronext Paris)YesOrdinary SharesFREURJul 2004
0RUGLSE (London Stock Exchange)YesOrdinary SharesGBEURJul 2004
EYWNDB (Deutsche Boerse AG)YesOrdinary SharesDEEURJul 2004
BIMWBAG (Wiener Boerse AG)YesOrdinary SharesATEURJul 2004
BIMPBATS-CHIXE (BATS 'Chi-X Europe')YesOrdinary SharesGBEURJul 2004

Biography

bioMérieux S.A. provides vitro diagnostic solutions systems for private and hospital laboratories, primarily for the diagnosis of infectious diseases. The company offers microbiology technology that involv ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/01 00:17
End of Day Share Price2020/09/29 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.